169 related articles for article (PubMed ID: 20103626)
21. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.
Kreitman RJ; Hassan R; Fitzgerald DJ; Pastan I
Clin Cancer Res; 2009 Aug; 15(16):5274-9. PubMed ID: 19671873
[TBL] [Abstract][Full Text] [Related]
22. Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies.
Cao Y; Marks JW; Liu Z; Cheung LH; Hittelman WN; Rosenblum MG
Oncogene; 2014 Jan; 33(4):429-39. PubMed ID: 23376850
[TBL] [Abstract][Full Text] [Related]
23. Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P.
Zhang J; Qiu S; Zhang Y; Merino M; Fetsch P; Avital I; Filie A; Pastan I; Hassan R
Anticancer Res; 2012 Dec; 32(12):5151-8. PubMed ID: 23225411
[TBL] [Abstract][Full Text] [Related]
24. A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity.
Weldon JE; Xiang L; Zhang J; Beers R; Walker DA; Onda M; Hassan R; Pastan I
Mol Cancer Ther; 2013 Jan; 12(1):48-57. PubMed ID: 23136186
[TBL] [Abstract][Full Text] [Related]
25. Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin.
Hassan R; Alewine C; Mian I; Spreafico A; Siu LL; Gomez-Roca C; Delord JP; Italiano A; Lassen U; Soria JC; Bahleda R; Thomas A; Steinberg SM; Peer CJ; Figg WD; Niederfellner G; Méresse Naegelen V; Pastan I
Cancer; 2020 Nov; 126(22):4936-4947. PubMed ID: 32870522
[TBL] [Abstract][Full Text] [Related]
26. New high affinity monoclonal antibodies recognize non-overlapping epitopes on mesothelin for monitoring and treating mesothelioma.
Zhang YF; Phung Y; Gao W; Kawa S; Hassan R; Pastan I; Ho M
Sci Rep; 2015 May; 5():9928. PubMed ID: 25996440
[TBL] [Abstract][Full Text] [Related]
27. Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas.
Li Q; Verschraegen CF; Mendoza J; Hassan R
Anticancer Res; 2004; 24(3a):1327-35. PubMed ID: 15274292
[TBL] [Abstract][Full Text] [Related]
28. Effect of antigen shedding on targeted delivery of immunotoxins in solid tumors from a mathematical model.
Pak Y; Pastan I; Kreitman RJ; Lee B
PLoS One; 2014; 9(10):e110716. PubMed ID: 25343405
[TBL] [Abstract][Full Text] [Related]
29. Mesothelin expression in human lung cancer.
Ho M; Bera TK; Willingham MC; Onda M; Hassan R; FitzGerald D; Pastan I
Clin Cancer Res; 2007 Mar; 13(5):1571-5. PubMed ID: 17332303
[TBL] [Abstract][Full Text] [Related]
30. chFRP5-ZZ-PE38, a large IgG-toxin immunoconjugate outperforms the corresponding smaller FRP5(Fv)-ETA immunotoxin in eradicating ErbB2-expressing tumor xenografts.
Mazor Y; Noy R; Wels WS; Benhar I
Cancer Lett; 2007 Nov; 257(1):124-35. PubMed ID: 17698286
[TBL] [Abstract][Full Text] [Related]
31. Novel immunocytokine IL12-SS1 (Fv) inhibits mesothelioma tumor growth in nude mice.
Kim H; Gao W; Ho M
PLoS One; 2013; 8(11):e81919. PubMed ID: 24260587
[TBL] [Abstract][Full Text] [Related]
32. Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression.
Hassan R; Miller AC; Sharon E; Thomas A; Reynolds JC; Ling A; Kreitman RJ; Miettinen MM; Steinberg SM; Fowler DH; Pastan I
Sci Transl Med; 2013 Oct; 5(208):208ra147. PubMed ID: 24154601
[TBL] [Abstract][Full Text] [Related]
33. HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity.
Bang S; Nagata S; Onda M; Kreitman RJ; Pastan I
Clin Cancer Res; 2005 Feb; 11(4):1545-50. PubMed ID: 15746059
[TBL] [Abstract][Full Text] [Related]
34. Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors.
Hagerty BL; Pegna GJ; Xu J; Tai CH; Alewine C
Biomolecules; 2020 Jun; 10(7):. PubMed ID: 32605175
[TBL] [Abstract][Full Text] [Related]
35. The role of mesothelin in tumor progression and targeted therapy.
Tang Z; Qian M; Ho M
Anticancer Agents Med Chem; 2013 Feb; 13(2):276-80. PubMed ID: 22721387
[TBL] [Abstract][Full Text] [Related]
36. Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro.
Hassan R; Lerner MR; Benbrook D; Lightfoot SA; Brackett DJ; Wang QC; Pastan I
Clin Cancer Res; 2002 Nov; 8(11):3520-6. PubMed ID: 12429643
[TBL] [Abstract][Full Text] [Related]
37. In vitro and in vivo activity of the low-immunogenic antimesothelin immunotoxin RG7787 in pancreatic cancer.
Hollevoet K; Mason-Osann E; Liu XF; Imhof-Jung S; Niederfellner G; Pastan I
Mol Cancer Ther; 2014 Aug; 13(8):2040-9. PubMed ID: 24928849
[TBL] [Abstract][Full Text] [Related]
38. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
Cao Y; Marks JD; Marks JW; Cheung LH; Kim S; Rosenblum MG
Cancer Res; 2009 Dec; 69(23):8987-95. PubMed ID: 19934334
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient-Derived Xenografts and Mesothelin as a Biomarker of Tumor Response.
Zhang J; Khanna S; Jiang Q; Alewine C; Miettinen M; Pastan I; Hassan R
Clin Cancer Res; 2017 Mar; 23(6):1564-1574. PubMed ID: 27635089
[No Abstract] [Full Text] [Related]
40. Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts.
Mossoba ME; Onda M; Taylor J; Massey PR; Treadwell S; Sharon E; Hassan R; Pastan I; Fowler DH
Clin Cancer Res; 2011 Jun; 17(11):3697-705. PubMed ID: 21521777
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]